Kane Biotech names biofilms expert Dr. Gregory Schultz as chief scientific officer, replacing Gordon Guay, who will be chairman of Kane's scientific advisory board; Schultz founded Institute for Wound Research at University of Florida, holds 36 patents

Sample article from our Tissue & Hygiene

WINNIPEG, Manitoba , April 26, 2022 (press release) –

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today the appointment of Gregory Schultz, PhD, a world renowned expert on biofilms, as Chief Scientific Officer (CSO).

“As a world-renowned expert in wound care and biofilms, we are honoured to welcome Dr. Schultz as Kane Biotech’s Chief Scientific Officer,” said Marc Edwards, Chief Executive Officer of Kane Biotech. Dr. Schultz’s appointment is a big step in confirming Kane as THE biofilm company, as we advance development and commercialization of our DispersinB® and coactiv+™ technologies, aimed at treating biofilm-mediated antimicrobial tolerance.”

Dr. Schultz is a Professor Emeritus of Obstetrics and Gynecology in the College of Medicine at the University of Florida where he established the interdisciplinary Institute for Wound Research (IWR), serving as Director for IWR for 32 years. Dr. Schultz is Past President of the Wound Healing Society, and past member of the National Pressure Injury Advisory Panel. He holds 36 patents and is the co-founder of two successful biotechnology companies.

“My career has focused on biofilm research,” said Dr. Schultz. ”We underestimate how big of a problem that biofilms are, as non-healing wounds are a major worldwide healthcare burden. The key to addressing this challenge is to treat associated biofilm formation,” said Dr. Schultz. “Kane’s technology has current and potential applications across a broad spectrum of biofilm-related issues in animal and human health. I am honored to lead the development of technologies to overcome the tolerance that bacteria in biofilms develop to patients’ immune systems, antibiotics, and anti-microbial technologies as Chief Scientific Officer.”

Gordon Guay, PhD, Kane’s outgoing Chief Scientific Officer, will continue to be closely involved in the company’s operations, and was recently appointed Chairman of Kane’s Scientific Advisory Board and Scientific Advisor to the CEO.

“I want to recognize the tremendous contributions Gordy has made to our company, enabling Kane to achieve significant milestones these past years. Thanks in large part to Gordy’s tremendous efforts, Kane Biotech is now uniquely positioned to become the industry leader in solving biofilm resistance challenges facing human and animal health sectors today,” said Edwards. “I’m grateful that I will be able to continue to count on Gordy’s support.”

About Gregory Schultz

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. A major area of his research focuses on defining the role of bacterial biofilms in stimulating chronic inflammation and proteases that impair healing in chronic wounds. Dr. Schultz has co-authored 400 scientific publications that have been cited over 23,000 times, has received $38 million USD in grant support as Principal Investigator or Co-investigator, is an inventor on 36 patents, and is a co-founder of two biotech companies in the areas of antimicrobial coatings and anti-scarring drugs. He served as President of the Wound Healing Society (1999-2001) and as a member of the National Pressure Ulcer Advisory Panel (2007-2010). In 2021, Dr. Schultz was elected a Fellow of the National Academy of Inventors.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:  

Marc EdwardsRay DupuisNicole Sendey

Chief Executive OfficerChief Financial OfficerInvestor Relations/PR

Kane Biotech IncKane Biotech IncKane Biotech Inc

medwards@kanebiotech.comrdupuis@kanebiotech.comnsendey@kanebiotech.com

+1 (514) 910-6991+1 (204) 298-2200+1 (250) 327-8675

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.


Source: Kane Biotech Inc.

Released April 5, 2022

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.